Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
A phase 2 trial of FPI-2265 in prostate cancer, run by Fusion Pharmaceuticals Inc., active and no longer recruiting.
Overview
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). is a phase 2 interventional study registered as NCT05219500 by Fusion Pharmaceuticals Inc., with 115 participants planned, started 2021-12-16 and due to reach its primary completion in 2025-05-30. Interventions recorded: FPI-2265. Conditions listed: Metastatic Castration Resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialFPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Shares FPI-2265, AstraZeneca, Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Shares FPI-2265, AstraZeneca, Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialPhase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Shares FPI-2265, AstraZeneca, Prostate cancer.
- TrialA Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialA Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
- TrialA Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.
- AgentActinium-225 FPI-2068
Shares FPI-2265, AstraZeneca.
- TrialA Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta
Shares Metastatic castration-resistant prostate cancer, Prostate cancer.